Is TAVR being used in the wrong patients?

Expensive transcatheter aortic valve replacements (TAVR) are being implanted in low and intermediate surgical risk patients with severe aortic stenosis despite a dearth of evidence for a clinical or cost benefit, surgeons say.

Associate Professor Jayme Bennetts, director of cardiac and thoracic surgery at Adelaide’s Flinders Medical Centre, says many interventional cardiologists have seized on the new technology – likely to be  Medicare-reimbursable soon – before